Nomacopan, a complement dual wokring inhibitor, is a potential blockbuster with widespread use and already has an established safety profile.

SaverOne is an Israeli company offering safe driver products for cars and fleets that have a huge Total Addressable Market. The stock may be severly undervalued.

Adamas One (JEWL) is a highly profitable company. There is no lack of demand for lab-grown diamonds and the company has already been producing at full production capacity since March of this year.

We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine.

RenovoRx takes existing chemotherapies and makes them more effective and less invasive, by being able to concentrate most of the chemotherapy agent on the tumor itself.

We give you seven reasons why SurgePays stock (SURG​​​​​​​) is an excellent bet for 2023...

We see a number of reasons to be positive about PLX shares in 2023 and investors should take note.

With an impressive upside potential and profitability now in sight, we think the current share price provides an attractive opportunity, despite the expected volatility.

DarioHeath is poised to be a $100M+ company running 60%+ gross margins, be profitable and cash generating.

We think Splash Beverage offers an exciting investment opportunity on the basis of their rapidly expanding distribution network and the potential of many of their latest distribution deals.

BNET is a high-risk/high-reward ESG play worth a closer look. Bion's patented technologies turn environmentally damaging waste into multiple useful products generating multiple income streams and has a leg up on the competition.

SurgePays is starting to look quite attractive, so we took a deep dive into SURG and spoke to management to get the inside scoop on what to expect.

Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.

The company was buffeted by the pandemic, a dividend cut, a car market growth decline, and negative currency effects but all of these seem to be disappearing.

Orgenesis is an innovative biotech company in the CGT (Cell & Gene Therapy) space.

While the company doesn't yet produce much in the way of revenues, it has stakes in multiple interesting opportunities and cash to last for quite a while. This is a high-risk, high-reward type of investment.